ArticleCancer medicine2026
Risk Factors and Comparative Safety of Anti-PD-1 Combination Therapies in Advanced Melanoma: A Nationwide Real-World Cohort Study From China.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic Time-Resolved Remodeling of the Immune Microenvironment After Resistance to BRAF/MEK Inhibitors in Melanoma: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroudDifferent anti-PD-1 combination therapies are used to improve response rate and combat drug resistance for melanoma in the real world of China. While the reported safety data has remained scarce, especially for the controversial use of interferon. Identification of risk factors and comparative safety of different therapies will be beneficial for physicians to make decisions on rational usage of immunotherapy.
methodsA nationwide retrospective cohort study consecutively collected advanced melanoma patients treated by anti-PD-1 based therapies between July 1, 2018 and June 30, 2023. Univariate and multivariable logistic regression analysis was performed to identify the association between the potential risk factors and the occurrence of immune-related adverse events (irAEs).
resultsA total of 508 advanced melanoma patients receiving PD-1 monotherapy (n = 181), PD-1 + tyrosine kinase inhibitors (TKI, n = 131), PD-1 + anti-vascular endothelial growth factor (anti-VEGF, n = 56), PD-1 + interferon Alfa-1b (IFN-α1b, n = 99) and PD-1 + IFN-α1b + TKI (n = 41) were included. There was no significant difference in irAEs across subtypes of melanoma. While for patients with autoimmune disease of psoriasis and lichen planus, recurrence was observed after immunotherapy. Baseline renal or hepatic dysfunction and prior TKI therapy were risk factors for grade 3-5 irAEs. Multivariate logistic regression model found that compared with PD-1 monotherapy therapy, PD-1 based combination therapies had greater toxicity but were tolerated, except PD-1 + IFN-α1b + TKI group. Notably, the triple therapy was associated with the highest risk of grade 3-5 irAEs (OR, 3.1; 95% CI: 1.2-8.1; p = 0.019), which led to a high rate of hospitalization and permanent treatment discontinuation.
conclusionOur results suggested that PD-1 + TKI, PD-1 + anti-VEGF, PD-1 + IFN-α1b combination therapies have some adverse events but are generally tolerated sufficiently for continuation of treatment. While the triple therapy PD-1 + IFN-α1b + TKI is not recommended because the benefits do not outweigh the risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.